Market Overview
Global oral delivery vaccines market size was valued at USD 2.52 billion in 2024. The market is projected to grow from USD 2.66 billion in 2025 to USD 3.69 billion by 2031, exhibiting a CAGR of 5.7% during the forecast period.
Oral delivery vaccines are pharmaceutical formulations administered through the mouth to induce immunity against pathogens. These vaccines stimulate both systemic and mucosal immune responses, offering advantages such as needle-free administration, improved patient compliance, and logistical benefits in mass vaccination programs. Major types include rotavirus, cholera, and oral polio vaccines, which collectively accounted for over 75% of market revenue in 2024.
USD 2.52 billion in 2024
2032 USD 3.69 billion by 2031
of 5.7%
Veterinary Use Segment Dominates the Market Due to Extensive Application in Livestock and Animal Health
Management
The market is segmented based on type into:
Human Use
Subtypes: Low molecular weight iron dextran and high molecular weight iron dextran
Veterinary Use
Iron Dextran Injection for human use is primarily administered to address anemia in patients with chronic kidney disease or those undergoing dialysis, where oral iron supplements may be insufficient. This segment benefits from growing awareness of nutritional deficiencies in developed regions. In contrast, the veterinary use segment leads the market owing to its widespread adoption in agriculture for preventing anemia in pigs, cattle, and other livestock, supporting global food production needs. The dominance of veterinary applications stems from the scale of animal husbandry operations, particularly in emerging economies where iron supplementation enhances animal growth and productivity.
By Application
The market is segmented based on application into:
Hospital
Pharmacy
Other
The hospital application segment holds a prominent position as Iron Dextran Injections are frequently used in inpatient and outpatient settings for rapid correction of severe iron deficiencies, especially in cases involving blood loss or malnutrition. Pharmacies contribute through retail distribution for outpatient prescriptions, catering to patients requiring ongoing therapy. The "other" category encompasses specialized uses in clinics, veterinary practices, and research facilities. Overall, the hospital segment's leadership is driven by the need for immediate intravenous administration under medical supervision, aligning with the rising incidence of anemia linked to chronic diseases and improving access to healthcare infrastructure worldwide.
Portable Neuromonitoring Device Market
https://www.24lifesciences.com
Our Key Players
Pharmacosmos A/S (Denmark)
Vetoquinol (France)
Bimeda (Ireland)
Swiss Parenterals (India)
Acino Pharma (Switzerland)
Bimeda (Ireland)
